Abstract |
The antioestrogen tamoxifen is of proven efficacy in inhibiting the growth of oestrogen receptor positive breast cancers in women. In rats, long-term dosing leads to the development of hepatocellular tumours. Tamoxifen in this species is a genotoxic carcinogen. Metabolic activation by cytochrome P450-dependent enzymes leads to DNA damage detectable by 32P-postlabelling. Factors important in the development of hepatocellular lesions were the nature and quantity of metabolism and promotion/progression of the DNA lesion by agents such as phenobarbital and cell proliferation. No evidence was found for tamoxifen-induced DNA damage in the livers of 7 women taking this drug therapeutically.
|
Authors | L L Smith, I N White |
Journal | Toxicology letters
(Toxicol Lett)
Vol. 82-83
Pg. 181-6
(Dec 1995)
ISSN: 0378-4274 [Print] Netherlands |
PMID | 8597049
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticarcinogenic Agents
- Estrogen Antagonists
- Tamoxifen
|
Topics |
- Animals
- Anticarcinogenic Agents
(pharmacology)
- Biotransformation
- Breast Neoplasms
(prevention & control)
- DNA Damage
- Estrogen Antagonists
(pharmacology)
- Female
- Humans
- Rats
- Tamoxifen
(pharmacokinetics, pharmacology)
|